In guidelines for weight management pharmacotherapy, which medication is not approved due to low efficacy?

• A. Lisdexamfetamine
• B. Liraglutide
• C. Orlistat
• D. Phentermine

Answer: (A)

The main idea is that pediatric weight-management medications are only approved when they show meaningful, sustained weight loss with acceptable safety in young people. Lisdexamfetamine, though a stimulant that can reduce appetite, has not demonstrated robust or durable weight loss in children and adolescents, and comes with risks like growth suppression, cardiovascular effects, mood changes, and potential for misuse. Because the balance of benefits and risks isn’t favorable for using it to treat obesity in youths, it isn’t approved for that indication. In contrast, other medications such as orlistat and liraglutide have shown measurable weight reductions in adolescents and are approved for use within specific age ranges, making them appropriate options in guidelines. Phentermine is mainly approved for adults, with limited pediatric data and safety considerations, so it isn’t used as a pediatric weight-management option in standard guidelines.